

























Aduro Biotech, Inc. (ADRO) Insider Thomas W. Dubensky Sells 50,000 Shares - BNB Daily





































 
















 

 













Daily Ratings & News for Aduro Biotech Inc.
Complete the form below to receive the latest headlines and analysts' recommendationsfor Aduro Biotech Inc. with our free daily email newsletter:



 




Follow @bnbdailynews





Recent Posts

KAMES CAPITAL plc Decreases Position in Ross Stores, Inc. (NASDAQ:ROST)
Efrain Rivera Sells 5,837 Shares of Paychex, Inc. (NASDAQ:PAYX) Stock
Credit Suisse AG Decreases Stake in Imperial Oil Ltd (IMO)
Union Pacific Corporation (NYSE:UNP) EVP Cameron A. Scott Sells 17,604 Shares
J.P. Marvel Investment Advisors LLC Has $874,000 Stake in Hershey Company (The) (NYSE:HSY)
SunTrust Banks, Inc. (NYSE:STI) Shares Bought by Park National Corp OH
Tudor Investment Corp ET AL Has $499,000 Stake in Discover Financial Services (DFS)
Enbridge Inc (NYSE:ENB) Shares Bought by Jane Street Group LLC
Ranger International Management LP Has $1,351,000 Stake in LyondellBasell Industries NV (NYSE:LYB)
Fox Run Management L.L.C. Buys 3,600 Shares of Wabco Holdings Inc. (WBC)
Clearbridge Investments LLC Has $1.28 Million Stake in EQT Corporation (EQT)
Regency Centers Corporation’s (NYSE:REG) “Equal Weight” Rating Reiterated at Barclays PLC
Insider Selling: Phibro Animal Health Corporation (NASDAQ:PAHC) Insider Sells 32,000 Shares of Stock
Virtu Financial, Inc. (VIRT) Downgraded by Citigroup Inc.
International Paper Company (IP) to Issue $0.46 Quarterly Dividend
Bank of the Ozarks (NASDAQ:OZRK) Posts Quarterly Earnings Results, Meets Expectations
Skandinaviska Enskilda Banken AB publ Continues to Hold Stake in Imperial Oil Ltd (IMO)
Fastenal Company (FAST) Announces Quarterly Dividend of $0.32
EMCORE Corporation (EMKR) Receives $12.00 Consensus Price Target from Brokerages
Kenneth Desgarennes Sells 20,318 Shares of Zayo Group Holdings, Inc. (ZAYO) Stock


 


Aduro Biotech, Inc. (ADRO) Insider Thomas W. Dubensky Sells 50,000 Shares

Posted by David Goldstein on Jul 22nd, 2017 // No Comments 

Aduro Biotech, Inc. (NASDAQ:ADRO) insider Thomas W. Dubensky sold 50,000 shares of the stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $11.33, for a total transaction of $566,500.00. Following the sale, the insider now directly owns 51,700 shares of the company’s stock, valued at approximately $585,761. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 
Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at 13.75 on Friday. The firm’s 50-day moving average is $11.45 and its 200-day moving average is $10.85. The company’s market capitalization is $961.30 million. Aduro Biotech, Inc. has a 1-year low of $8.75 and a 1-year high of $16.43. 




Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.07. Aduro Biotech had a negative return on equity of 35.35% and a negative net margin of 166.85%. The firm had revenue of $3.77 million for the quarter, compared to analyst estimates of $3.74 million. Analysts forecast that Aduro Biotech, Inc. will post ($1.41) earnings per share for the current fiscal year. 
ILLEGAL ACTIVITY WARNING: This story was originally published by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.baseball-news-blog.com/2017/07/22/insider-selling-aduro-biotech-inc-adro-insider-sells-566500-00-in-stock-updated.html. 


 Get Aduro Biotech Inc. alerts:



Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in Aduro Biotech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock valued at $101,571,000 after buying an additional 791,770 shares during the period. Norges Bank purchased a new stake in Aduro Biotech during the fourth quarter valued at $3,266,000. Goldman Sachs Group Inc. increased its stake in shares of Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock valued at $2,545,000 after buying an additional 181,734 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock valued at $1,955,000 after buying an additional 160,800 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in shares of Aduro Biotech during the first quarter valued at about $853,000. 35.65% of the stock is currently owned by institutional investors. 
Several research firms have recently commented on ADRO. Zacks Investment Research cut shares of Aduro Biotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 2nd. HC Wainwright assumed coverage on shares of Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price target for the company. Canaccord Genuity reissued a “buy” rating and set a $30.00 price target on shares of Aduro Biotech in a research report on Wednesday, May 3rd. Cowen and Company assumed coverage on shares of Aduro Biotech in a research report on Tuesday. They set an “outperform” rating for the company. Finally, Rodman & Renshaw assumed coverage on shares of Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $19.00.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. 

 
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 





















Latest News




Leave a Reply

Click here to cancel reply.




Name (Required) 



Mail (will not be published) (Required) 



Website






 






























    Thomas Dubensky | ADURO BIOTECH, INC. | ZoomInfo.com


ADRO Thomas W. Dubensky Insider Trades for Aduro Biotech Inc.


































X

Tweet
 

Share this bulletin

Get news bulletins by email

Bulletin

Amazon tagged with 3.5% loss early Friday, pacing consumer-discretionary skid »
        




Investor Alert







New York Markets Close in:



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Aduro Biotech Inc.

                  NASDAQ: ADRO
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Aduro Biotech Inc.



Market open
 --Real time quotes
Jul 28, 2017, 9:57 a.m.


ADRO

/quotes/zigman/48476114/composite


$
13.10




Change

-0.15
-1.13%

Volume
Volume 9,129
Real time quotes








/quotes/zigman/48476114/composite
Previous close

$
			13.25
		


$
				13.10
			
Change

-0.15
-1.13%





Day low
Day high
$13.00
$13.35










52 week low
52 week high

            $8.75
        

            $16.43
        


















Insider Activity


Individual




Thomas W. Dubensky



Dr. Thomas W. Dubensky, Jr. PhD, is Chief Scientific Officer at Aduro BioTech, Inc.
Dr. Dubensky was previously employed as Chief Scientific Officer by Anza Therapeutics, Inc., Vice President-Research by Cerus Corp., Chief Scientific Officer by Immune Design Corp., a Principal by Chiron Viagene, Inc., Scientific Director by Chiron Corp., and Vice President by Onyx Pharmaceuticals, Inc.
He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from the University of Colorado Health Sciences Center.



Transactions


Date
Shares
Transaction
Value





07/06/2017
4,512


 
Disposition at $11.23 per share.


50,670


07/06/2017
4,512


 
Derivative/Non-derivative trans. at $0.52 per share.


2,346


07/05/2017
33,688


 
Disposition at $11.46 per share.


386,065


07/05/2017
33,688


 
Derivative/Non-derivative trans. at $0.52 per share.


17,517


07/03/2017
11,800


 
Disposition at $11.02 per share.


130,036


07/03/2017
11,800


 
Derivative/Non-derivative trans. at $0.52 per share.


6,136


06/05/2017
17,577


 
Disposition at $9.99 per share.


175,595


06/05/2017
17,577


 
Derivative/Non-derivative trans. at $0.52 per share.


9,140


06/02/2017
48,753


 
Disposition at $10.1 per share.


492,406


06/02/2017
48,753


 
Derivative/Non-derivative trans. at $0.52 per share.


25,351


06/01/2017
77,971


 
Disposition at $10 per share.


779,710


06/01/2017
77,971


 
Derivative/Non-derivative trans. at $0.52 per share.


40,544


05/12/2017
4,299


 
Disposition at $9.92 per share.


42,647


05/12/2017
4,299


 
Derivative/Non-derivative trans. at $0.52 per share.


2,235


05/11/2017
1,400


 
Disposition at $9.91 per share.


13,874


05/11/2017
1,400


 
Derivative/Non-derivative trans. at $0.52 per share.


728


03/09/2017
25,000


 
Disposition at $10.96 per share.


274,000


03/09/2017
6,931


 
Derivative/Non-derivative trans. at $1.45 per share.


10,049


03/09/2017
3,165


 
Derivative/Non-derivative trans. at $0.52 per share.


1,645


03/09/2017
14,904


 
Derivative/Non-derivative trans. at $0.52 per share.


7,750


01/03/2017
25,000


 
Disposition at $11.16 per share.


279,000


01/03/2017
25,000


 
Derivative/Non-derivative trans. at $0.52 per share.


13,000


12/01/2016
25,000


 
Disposition at $10.94 per share.


273,500


12/01/2016
2,875


 
Derivative/Non-derivative trans. at $0.52 per share.


1,495


12/01/2016
8,262


 
Derivative/Non-derivative trans. at $0.52 per share.


4,296


12/01/2016
13,863


 
Derivative/Non-derivative trans. at $1.45 per share.


20,101


11/10/2016
25,000


 
Disposition at $14.78 per share.


369,500


11/10/2016
3,938


 
Derivative/Non-derivative trans. at $0.52 per share.


2,047


11/10/2016
21,062


 
Derivative/Non-derivative trans. at $1.45 per share.


30,539


10/03/2016
25,000


 
Disposition at $12.68 per share.


317,000


10/03/2016
9,476


 
Derivative/Non-derivative trans. at $0.52 per share.


4,927


10/03/2016
15,524


 
Derivative/Non-derivative trans. at $1.45 per share.


22,509


09/12/2016
39,900


 
Award at $0 per share.


0


09/01/2016
25,000


 
Disposition at $14.03 per share.


350,750


09/01/2016
8,593


 
Derivative/Non-derivative trans. at $0.52 per share.


4,468


09/01/2016
16,407


 
Derivative/Non-derivative trans. at $1.45 per share.


23,790


08/11/2016
25,000


 
Disposition at $15.18 per share.


379,500


08/11/2016
12,500


 
Derivative/Non-derivative trans. at $0.52 per share.


6,500


08/11/2016
12,500


 
Derivative/Non-derivative trans. at $1.45 per share.


18,125


07/05/2016
25,000


 
Disposition at $11.61 per share.


290,250


07/05/2016
11,061


 
Derivative/Non-derivative trans. at $0.52 per share.


5,751


07/05/2016
13,939


 
Derivative/Non-derivative trans. at $1.45 per share.


20,211


05/16/2016
905


 
Disposition at $8.2 per share.


7,421


01/04/2016
3,771


 
Disposition at $27.02 per share.


101,893


01/04/2016
11,229


 
Disposition at $26.15 per share.


293,639


01/04/2016
8,068


 
Derivative/Non-derivative trans. at $7.45 per share.


60,106


01/04/2016
6,932


 
Derivative/Non-derivative trans. at $1.45 per share.


10,051


12/01/2015
100


 
Disposition at $30.06 per share.


3,006


12/01/2015
3,987


 
Disposition at $29.45 per share.


117,418


12/01/2015
400


 
Disposition at $30.06 per share.


12,024


12/01/2015
3,249


 
Disposition at $29.43 per share.


95,619


12/01/2015
1,890


 
Disposition at $29.81 per share.


56,341


12/01/2015
20,374


 
Disposition at $29.14 per share.


593,699


12/01/2015
4,087


 
Derivative/Non-derivative trans. at $7.45 per share.


30,448


12/01/2015
3,649


 
Derivative/Non-derivative trans. at $0.45 per share.


1,642


12/01/2015
22,264


 
Derivative/Non-derivative trans. at $1.45 per share.


32,282


11/17/2015
18,520


 
Disposition at $28.75 per share.


532,450


11/17/2015
1,999


 
Disposition at $27.7 per share.


55,373


11/17/2015
20,519


 
Derivative/Non-derivative trans. at $1.45 per share.


29,752


11/16/2015
1,470


 
Disposition at $27.5 per share.


40,425


11/16/2015
700


 
Disposition at $28.33 per share.


19,831


11/16/2015
8,781


 
Disposition at $27.5 per share.


241,478


11/16/2015
9,481


 
Derivative/Non-derivative trans. at $1.45 per share.


13,747





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Stephen T. Isaacs 
Chairman, President & Chief Executive Officer




Mr. Gregory W. Schafer 
Chief Operating Officer




Ms. Jennifer  Lew 
Senior Vice President-Finance




Dr. Justin  Skoble 
Vice President-Technical Operations




Ms. Aimee Luck Murphy 
Vice President-Clinical Development & Operations




Dr. Natalie R. Sacks 
Chief Medical Officer




Dr. Dirk G. Brockstedt 
Executive Vice President-Research & Development




Dr. Thomas W. Dubensky 
Chief Scientific Officer




Ms. Liana  Wu 
Vice President-Commercial




Ms. Susan  Lehner 
Media Contact




Ms. Sylvia R. Wheeler 
Senior VP-Investor Relations & Corporate Affairs




Ms. Nancy  Kaplan 
VP-Human Resources & Facility Operations




Mr. Blaine  Templeman 
Secretary, Executive VP & General Counsel




Ms. Michele  DeVries 
Vice President-Regulatory Affairs




Dr. Stephen A. Sherwin 
Independent Director




Dr. Lok Chung  Chan 
Independent Director




Dr. Francis Patrick McCormick 
Independent Director




Ms. Stephanie Monaghan O'Brien 
Lead Independent Director




Mr. William Mariner Greenman 
Independent Director




Mr. Ross  Haghighat 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:00 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
10:00aTreasury to wind down the myRA retirement savings program
9:58aCan Christopher Nolan’s ‘Dunkirk’ crack China’s market? 
9:55aThis type of investing could save the world — just don’t expect outperformance, too
9:54aThese tips can help advisers attract — and keep — high net worth clients
9:54aA menacing pattern has revealed itself in the stock market
9:53aTeaching people how to invest is one of the best marketing moves an adviser can make
9:45aA case for buying the freakin’ dip with Amazon, as the Mooch might now say
9:43aConsumer-discretionary sector slides as Amazon shares drop on results
9:42aShares of newspaper publisher McClatchy are up more than 2%
9:42a5 cities where you can buy a HUGE house for $100,000 or less
9:42aHow advisers can fight the ‘crisis of trust’ in financial services
9:38aBREAKINGStock market opens lower as Wall Street resumes tech selling
9:38aDestination Maternity plummets toward record low after merger deal terminated
9:38aThis is how Congress could craft a bipartisan health-care bill
9:36aMeet the ‘Hamilton’ actors who fly cross-country and play up to 18 roles in the hit show
9:34aTrump’s time—and political capital—is quickly running out
9:33aConsumer Discretionary Select Sector SPDR ETF falls 1% as Amazon.com sinks 4.1%
9:31aDow Jones Industrial Average opens less than 0.1% lower
9:31aS&P 500 opens down 0.2%
9:31aNasdaq Composite Index opens down 0.6%
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,762.83

-33.72
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,357.04

-25.15
-0.39%





s&p 500

/quotes/zigman/3870025/realtime
2,468.04

-7.38
-0.30%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Insider Trading - Dubensky Thomas W. - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Dubensky Thomas W.





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2017-01-03Sale
2017-01-055:15 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$11.16
$278,990
64,900(Direct)
View


2016-12-01Sale
2016-12-057:21 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$10.94
$273,500
216,736(Direct)
View


2016-11-10Sale
2016-11-147:00 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$14.78
$369,408
194,083(Direct)
View


2016-10-03Sale
2016-10-055:18 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$12.68
$316,908
215,145(Direct)
View


2016-09-01Sale
2016-09-024:24 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$14.03
$350,775
230,669(Direct)
View


2016-08-11Sale
2016-08-125:43 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$15.18
$379,500
247,076(Direct)
View


2016-07-05Sale
2016-07-076:38 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$11.61
$290,250
259,576(Direct)
View


2016-05-16Sale
2016-05-187:11 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
905
$8.2
$7,421
0(Direct)
View


2016-01-04Sale
2016-01-066:18 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
15,000
$26.37
$395,531
273,515(Direct)
View


2015-12-01Sale
2015-12-026:24 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
30,000
$29.27
$878,104
280,447(Direct)
View


2015-11-16Sale
2015-11-188:11 pm
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
31,470
$28.27
$889,556
323,230(Direct)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2017-01-03Exercise
2017-01-055:15 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$0.52
64,900(Direct)
View


2017-01-03Exercise
2017-01-055:15 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
25,000
$0.52
64,900(Direct)
View


2016-12-12Option Award
2016-12-149:05 pm
N/A2026-12-11
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
29,800
$11.15
29,800(Direct)
View


2016-12-01Exercise
2016-12-057:21 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
13,863
$1.45
216,736(Direct)
View


2016-12-01Exercise
2016-12-057:21 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
8,262
$0.52
216,736(Direct)
View


2016-12-01Exercise
2016-12-057:21 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
2,875
$0.52
216,736(Direct)
View


2016-12-01Exercise
2016-12-057:21 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
13,863
$1.45
216,736(Direct)
View


2016-12-01Exercise
2016-12-057:21 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
8,262
$0.52
216,736(Direct)
View


2016-12-01Exercise
2016-12-057:21 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
2,875
$0.52
216,736(Direct)
View


2016-11-10Exercise
2016-11-147:00 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
21,062
$1.45
194,083(Direct)
View


2016-11-10Exercise
2016-11-147:00 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
3,938
$0.52
194,083(Direct)
View


2016-11-10Exercise
2016-11-147:00 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
21,062
$1.45
194,083(Direct)
View


2016-11-10Exercise
2016-11-147:00 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
3,938
$0.52
194,083(Direct)
View


2016-10-03Exercise
2016-10-055:18 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
15,524
$1.45
215,145(Direct)
View


2016-10-03Exercise
2016-10-055:18 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
9,476
$0.52
215,145(Direct)
View


2016-10-03Exercise
2016-10-055:18 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
15,524
$1.45
215,145(Direct)
View


2016-10-03Exercise
2016-10-055:18 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
9,476
$0.52
215,145(Direct)
View


2016-09-12Option Award
2016-09-144:13 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
39,900
$0
39,900(Direct)
View


2016-09-01Exercise
2016-09-024:24 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
16,407
$1.45
230,669(Direct)
View


2016-09-01Exercise
2016-09-024:24 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
8,593
$0.52
230,669(Direct)
View


2016-09-01Exercise
2016-09-024:24 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
16,407
$1.45
230,669(Direct)
View


2016-09-01Exercise
2016-09-024:24 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
8,593
$0.52
230,669(Direct)
View


2016-08-11Exercise
2016-08-125:43 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
12,500
$1.45
247,076(Direct)
View


2016-08-11Exercise
2016-08-125:43 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
12,500
$0.52
247,076(Direct)
View


2016-08-11Exercise
2016-08-125:43 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
12,500
$1.45
247,076(Direct)
View


2016-08-11Exercise
2016-08-125:43 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
12,500
$0.52
247,076(Direct)
View


2016-07-05Exercise
2016-07-076:38 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
13,939
$1.45
259,576(Direct)
View


2016-07-05Exercise
2016-07-076:38 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
11,061
$0.52
259,576(Direct)
View


2016-07-05Exercise
2016-07-076:38 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
13,939
$1.45
259,576(Direct)
View


2016-07-05Exercise
2016-07-076:38 pm
N/A2021-10-23
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
11,061
$0.52
259,576(Direct)
View


2016-06-10Option Award
2016-06-108:32 pm
N/A2026-06-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
30,100
$11.99
30,100(Direct)
View


2016-01-04Exercise
2016-01-066:18 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
6,932
$1.45
273,515(Direct)
View


2016-01-04Exercise
2016-01-066:18 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
8,068
$7.45
273,515(Direct)
View


2016-01-04Exercise
2016-01-066:18 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
6,932
$1.45
273,515(Direct)
View


2016-01-04Exercise
2016-01-066:18 pm
N/A2025-03-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
8,068
$7.45
273,515(Direct)
View


2015-12-10Option Award
2015-12-146:46 pm
N/A2025-12-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
15,000
$30.16
15,000(Direct)
View


2015-12-01Exercise
2015-12-026:24 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
22,264
$1.45
280,447(Direct)
View


2015-12-01Exercise
2015-12-026:24 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
3,649
$0.45
280,447(Direct)
View


2015-12-01Exercise
2015-12-026:24 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
4,087
$7.45
280,447(Direct)
View


2015-12-01Exercise
2015-12-026:24 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
22,264
$1.45
280,447(Direct)
View


2015-12-01Exercise
2015-12-026:24 pm
N/A2020-03-18
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
3,649
$0.45
280,447(Direct)
View


2015-12-01Exercise
2015-12-026:24 pm
N/A2025-03-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
4,087
$7.45
280,447(Direct)
View


2015-11-16Exercise
2015-11-188:11 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
9,481
$1.45
323,230(Direct)
View


2015-11-16Exercise
2015-11-188:11 pm
N/AN/A
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
20,519
$1.45
323,230(Direct)
View


2015-11-16Exercise
2015-11-188:11 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
9,481
$1.45
323,230(Direct)
View


2015-11-16Exercise
2015-11-188:11 pm
N/A2025-01-09
Aduro Biotech Inc
ADRO
Dubensky Thomas W.Chief Scientific Officer
20,519
$1.45
323,230(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 09:00:19 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








 

Leadership | Aduro Biotech



















Pioneering Immunotherapy.
Transforming Lives.


Leadership








Stephen T. Isaacs

Chairman, President and CEO



Thomas W. Dubensky, Jr., Ph.D.

Chief Scientific Officer





Natalie R. Sacks, M.D.

Chief Medical Officer



Gregory W. Schafer

Chief Operating Officer





Hans van Eenennaam, Ph.D.

Chief Operational Officer, Aduro Biotech Europe



Andrea van Elsas, Ph.D.

Chief Scientific Officer, Aduro Biotech Europe



 


Dirk G. Brockstedt, Ph.D.

Executive Vice President, Research & Development



Jennifer Lew

Senior Vice President, Finance





Quoc Le-Nguyen

Senior Vice President, Chemistry, Manufacturing and Control



Blaine Templeman

Executive Vice President, General Counsel and Secretary





Sylvia Wheeler

Senior Vice President, Corporate Affairs and Investor Relations




 


Michele DeVries

Vice President, Regulatory Affairs



Celeste Ferber

Vice President, Associate General Counsel





Nancy Kaplan

Vice President, Human Resources and Facility Operations



Anne Moon, Ph.D.

Vice President, Project Management





Aimee Murphy

Vice President, Clinical Development and Operations



Justin Skoble, Ph.D.

Vice President, Technical Operations





Liana Wu

Vice President, Commercial





Stephen T. Isaacs

Chairman, President and CEO


Stephen T. Isaacs has served as our Chairman, President and Chief Executive Officer since 2008. Prior to Aduro, in 1991, Mr. Isaacs founded Cerus Corporation, a biomedical products company that commercialized the Intercept Blood Systems. He served as President and Chief Executive Officer of Cerus from 1991 to 2004. Prior to Cerus, Mr. Isaacs founded and served as Chief Executive Officer and President of HRI Associates and HRI Research, both biotechnology companies focused on research and development. He held a non-teaching faculty position in the Department of Chemistry at the University of California, Berkeley, from 1978 to 1986. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents. Mr. Isaacs holds a B.A. degree in Biochemistry from University of California, Berkeley, and had graduate training in organic chemistry in the Ph.D. program in the Department of Chemistry at Berkeley.


Thomas W. Dubensky Jr., Ph.D.

Chief Scientific Officer


Thomas W. Dubensky Jr., Ph.D., has served as our Chief Scientific Officer since September 2011. From 2009 to 2011, Dr. Dubensky served as Chief Scientific Officer of Immune Design where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. Prior to this, in 2007 he co-founded and served as Chief Scientific Officer of Anza Therapeutics, a biotechnology company that was spun out from Cerus Corporation where he had served as Vice President of Research for the five years prior. During this time, Dr. Dubensky helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes, which serves as the technology basis for Aduro’s LADD platform. Earlier in his career, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses and plasmid DNA at a number of biotechnology companies, including Viagene, Chiron Corporation and Onyx Pharmaceuticals. Dr. Dubensky has co-authored more than 70 scientific papers and is an inventor on 35 issued U.S. patents with multiple pending applications. Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley, and his Ph.D. at the University of Colorado Health Sciences Center. He conducted his post-doctoral fellowship at Harvard Medical School in the Department of Pathology.


Natalie R. Sacks, M.D.

Chief Medical Officer

Natalie Sacks, M.D., has served as our Chief Medical Officer since September 2016. Prior to joining Aduro, Dr. Sacks served as an advisor on development strategy for multiple firms. Previously, she was Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen) where she played a key role in the development and approval of Kyprolis®, an FDA-approved therapy for the treatment of relapsed or refractory multiple myeloma, and in business development strategy. Prior to that, she served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, with responsibilities ranging from IND filings to late-stage development, including late-stage development of Cometriq™, an FDA-approved therapy for the treatment of medullary thyroid cancer. Earlier in her career, Dr. Sacks served as Vice President of Clinical Development at Cell Genesys, a company focused on the development of cancer vaccines and engineered chimeric antigen receptor (CAR) T cells. Prior to her tenure in biotechnology, she served in a variety of research and analytical roles at academic institutions and companies, including Massachusetts General Hospital, Medical College of Pennsylvania, and ICI-Stuart Pharmaceuticals. In addition to her industry experience, Dr. Sacks holds an active faculty appointment at the University of California, San Francisco, where she is an assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College.


Gregory W. Schafer

Chief Operating Officer


Gregory W. Schafer has served as our Chief Operating Officer since July 2013. Prior to joining Aduro, he served as Chief Financial Officer of Jennerex Biotherapeutics (acquired by Sillajen), a privately held biotechnology company, from June 2010 to July 2013, where he was responsible for finance, accounting, planning, investor relations and treasury functions. From April 2006 to January 2009, he served as Chief Financial Officer of Onyx Pharmaceuticals (acquired by Amgen) where he was responsible for finance, accounting, risk management and strategic and operational planning. Earlier in his career, Mr. Schafer served as Chief Financial Officer and Vice President of Finance for IntraBiotics Pharmaceuticals and Cerus Corporation. Prior to entering the field of biotechology, he worked as a management consultant for Deloitte & Touche LLP. He received his M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles, and a B.S.E. in mechanical engineering from the University of Pennsylvania.


Hans van Eenennaam, Ph.D.

Chief Operational Officer, Aduro Biotech Europe


Hans van Eenennaam, Ph.D., became Chief Operational Officer of Aduro Biotech Europe in November 2015. Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operational officer of BioNovion, a company he co-founded in 2011 to focus on the development of innovative therapeutic antibodies in the field of immune oncology. Earlier in his career, he held numerous positions of increasing responsibility at Organon in Oss, Netherlands, and the Organon Research Center in Cambridge, Massachusetts, which was acquired by Schering-Plough Corporation in 2007 and later by Merck & Co. He led the discovery and development of therapeutic monoclonal antibodies and small molecule entities in the field of oncology and immunology. While at Organon, Dr. van Eenennaam, in cooperation with a team of scientists, discovered pembrolizumab (Keytruda®), a humanized therapeutic antibody acquired by Merck and approved in 2014 by the U.S. Food and Drug Administration for the treatment of melanoma and subsequently for additional indications including, non-small cell lung cancer and head and neck cancer. In 2016, he and colleagues were honored by the Intellectual Property Owner’s Association with the 43rd Annual Inventor of the Year Award. He is named as inventor on seven pending and granted patent families, including the patents claiming Keytruda, and author on over 25 publications. Dr. van Eenennaam received his doctorate in autoimmune biochemistry (cum laude) from Radboud University in Nijmegen, Netherlands.


Andrea van Elsas, Ph.D.

Chief Scientific Officer, Aduro Biotech Europe


Andrea van Elsas became Chief Scientific Officer of Aduro Biotech Europe in November 2015. Prior to its acquisition by Aduro in 2015, Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. From 1999 to 2011, he held numerous positions at Organon in Oss, The Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. As a postdoctoral researcher from 1997-1999, Andrea worked at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy® (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.


Dirk G. Brockstedt, Ph.D.

Executive Vice President, Research & Development


Dirk G. Brockstedt, Ph.D., joined Aduro in April 2009 and has served as our Senior Vice President of Research and Development since September 2011. Prior to joining Aduro, Dr. Brockstedt held various positions of increasing responsibility in the immunotherapy group at Cerus Corporation, culminating as Director of Immunology. Earlier in his career, Dr. Brockstedt worked as a scientist at Aventis in the Immunotherapy and Anti-Angiogenesis group from 1999 until 2002, focused on developing novel anti-cancer therapies. He has co-authored 40 scientific papers and is a named inventor on five issued patents and several pending applications. Dr. Brockstedt holds a Diploma/Masters of Science in Microbiology from the University of Kiel and earned his Ph.D. from the University of Kiel and Stanford University, the latter at which he served as a post-doctoral fellow at the Stanford School of Medicine in the department of Pathology.


Jennifer Lew

Senior Vice President, Finance


Jennifer Lew joined Aduro in October 2013 and has served as our Senior Vice President of Finance since January 2015. Prior to joining Aduro, from 2004 to 2013, Ms. Lew held various positions of increasing responsibility at Dynavax Technologies, culminating as Vice President of Finance and Principal Accounting Officer responsible for all accounting and finance operations. Earlier in her career Ms. Lew served as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Ms. Lew earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).


Quoc Le-Nguyen

Senior Vice President, Chemistry, Manufacturing and Control


Quoc Le-Nguyen joined Aduro in September 2015 and has served as our Senior Vice President of Chemistry, Manufacturing and Control (CMC) since September 2016. He brings over 25 years of experience in biopharmaceutical operations, having held positions of increasing responsibility at both large pharmaceutical and start-up companies. Prior to joining Aduro, Mr. Le-Nguyen spent seven years at Bayer Healthcare as the Vice President of Technical Operations. Before Bayer, he served at Chiron Corporation (and Novartis AG) as Director of Manufacturing Operations. Earlier in his career, he served as Senior Manager of Manufacturing Operations at BioMarin Pharmaceutical, where he played an integral role in bringing the company’s lead drug candidate from Phase 3 to commercial launch. Mr. Le-Nguyen holds a B.S. from University of California, Davis in Biochemistry.


Blaine Templeman

Executive Vice President, General Counsel and Secretary


Blaine Templeman joined Aduro as Executive Vice President, General Counsel and Secretary in September 2015. He brings over 20 years of experience counseling biotechnology companies in the development and commercialization of their products. Prior to joining Aduro, Mr. Templeman was a corporate and intellectual property partner at Arnold & Porter LLP, where he counseled U.S. and international clients on the protection, development and commercialization of their products, intellectual property portfolios, contract manufacturing, clinical trials, research and outsourcing. His transactional experience includes a variety of collaborations, licensing transactions, mergers and acquisitions, asset sales, manufacturing and distribution arrangements and co-promotion transactions. Before Arnold & Porter LLP, he was a partner at Heller Ehrman. Mr. Templeman holds a J.D. from New York University and a B.S. from Oral Roberts University.


Sylvia Wheeler

Senior Vice President, Corporate Affairs and Investor Relations


Sylvia Wheeler joined Aduro as Senior Vice President, Corporate Affairs and Investor Relations in January 2015. She brings over 20 years of experience in the biopharmaceutical industry, having served in a number of executive management roles encompassing investor and media relations, as well as corporate and product communications. Prior to joining Aduro, Ms. Wheeler served as Vice President of Investor Relations and Corporate Affairs at Relypsa after having served this same role for Hyperion Therapeutics. Earlier in her career, she was Vice President, Corporate Communications at Affymax where, over a six-year-period, she supported the company’s transition from a research and development company to a commercial organization with its first marketed product. Ms. Wheeler held similar communications roles at Depomed, Cerus Corporation and Coulter Pharmaceutical. Ms. Wheeler holds an M.B.A. from University of San Francisco and a B.A. in Biology from San Francisco State University.


Michele DeVries

Vice President, Regulatory Affairs

Michele DeVries joined Aduro in 2013 and currently serves as Vice President of Regulatory Affairs. She is responsible for all aspects of regulatory strategy, implementation and oversight of Aduro’s proprietary, partnered and licensed programs, both in the U.S. and internationally. Prior to Aduro, Ms. DeVries served as Director of Regulatory Affairs for Intarcia Therapeutics. In this role she managed key regulatory aspects of Intarcia’s drug delivery system, served as the primary contact for regulatory authorities, and was responsible for all aspects of routine and specialized regulatory submissions, including preparation for launch of four global Phase 3 studies. Before Intarcia, she held escalating regulatory affairs positions at VaxGen, InterMune and Tularik. She received her B.S. in Chemical Engineering from the University of Minnesota.


Celeste Ferber

Vice President, Associate General Counsel

Celeste Ferber joined Aduro in 2016 and currently serves as Vice President, Associate General Counsel. Prior to Aduro, she was with Shearman & Sterling LLP, where she served as counsel in the capital markets group. Ms. Ferber has over 15 years of experience advising public and private companies on corporate and finance matters, including securities offerings, mergers, acquisitions and strategic transactions, corporate governance and securities law compliance. Before Shearman & Sterling, Ms. Ferber was counsel at Morrison & Foerster LLP working in their Palo Alto, Hong Kong and San Diego offices. Ms. Ferber received her J.D. from the University of California, Hastings College of Law and her B.A. in Economics from Bucknell University. She is the author of numerous publications regarding legal matters.


Nancy Kaplan

Vice President, Human Resources and Facility Operations


Nancy Kaplan joined Aduro in 2008 and currently serves as Aduro’s Vice President of Human Resources and Facility Operations. Prior to Aduro, Ms. Kaplan worked with a wide variety of small biotech companies, applying her broad generalist skill set to establish and bolster finance, human resources, facility management, grant administration and investor relations functions. In addition, she was Marketing Communications Manager at Applied Biosystems and supervised biotech accounts at Lena Chow Advertising. Earlier in her career, Ms. Kaplan was part of the founding group at Invitron Corp, a mammalian cell contract manufacturer. Ms. Kaplan holds a B.S. in Agronomy from Oregon State University.


Anne Moon, Ph.D.

Vice President, Project Management


Anne Moon, Ph.D., joined Aduro in 2014 and currently serves as Vice President of Project Management. Prior to Aduro, Dr. Moon was a founding team member of Jennerex Biotherapeutics (acquired by SillaJen), where she served as Vice President of Product Development. Earlier in her career, Dr. Moon was part of the start-up team at Cytokinetics, establishing the cell-based screening program and served as Project Manager of the oncolytic virus program at Onyx Pharmaceuticals (acquired by Amgen) after completing postdoctoral work within the small molecule therapeutics program targeting small GTPases. She received her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and her B.A. in Biology from Harvard University.


Aimee Murphy

Vice President, Clinical Development and Operations


Ms. Murphy joined Aduro in 2009 and currently serves as Vice President of Clinical Development and Operations. Prior to Aduro, Ms. Murphy advanced the development of the LADD (live, attenuated double-deleted) immunotherapy platform at both Cerus Corporation and Anza Therapeutics, where she managed the first Phase 1 studies that led to Aduro's existing LADD clinical programs. Prior to focusing on LADD, she worked on the development of prophylactic vaccines and drugs for oncology and infectious diseases at VaxGen, Coulter Pharmaceuticals, and Shaman Pharmaceuticals. Additionally, Ms. Murphy brings experience in quality assurance from Bayer Pharmaceuticals. She holds a B.S. in Biology from Pepperdine University.


Justin Skoble, Ph.D.

Vice President, Technical Operations


Justin Skoble, Ph.D., joined Aduro in 2009 and currently serves as Aduro’s Vice President of Technical Operations. Prior to Aduro, Dr. Skoble held positions with increasing responsibilities in the molecular biology and process development departments at Anza Therapeutics and Cerus Corporation. He earned his B.A. in Biology from Vassar College and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, in the laboratory of Dr. Daniel Portnoy. Additionally, Dr. Skoble performed postdoctoral work at the University of California, San Francisco (UCSF), in the laboratory of Dr. Jeff Cox, Professor of Microbiology and Immunology at UCSF.


Liana Wu

Vice President, Commercial


Liana Wu joined Aduro in April 2015 as Vice President, Commercial, bringing with her over 17 years of commercial experience in the biotechnology industry and a successful track record in brand development and product launches. Prior to Aduro, Ms. Wu spent nine years at Onyx Pharmaceuticals (acquired by Amgen) where she was most recently Vice President, Oncology Franchise. While at Onyx, she was instrumental in overseeing the collaboration with Bayer for Nexavar and Stivarga in the United States. Earlier in her career, Ms. Wu held several sales and marketing positions at Genentech, with responsibilities associated with the company’s key oncology brands, including Rituxan, Herceptin, and Tarceva. Ms. Wu holds a Master’s in Public Health from The Johns Hopkins University and a B.S. in Economics from the Wharton School at the University of Pennsylvania.










Leadership


Board of Directors


Scientific Advisory Board


Culture


Global Headquarters


Community Affairs








Home


About Us



Leadership


Board of Directors


Scientific Advisory Board


Culture


Global Headquarters


Community Affairs





Pipeline



Clinical Trials


Access to Our Investigational Agents





Technology



Immunotherapy


LADD


STING Pathway


B-select Antibodies


Scientific Publications


Intellectual Property





Partnerships


Media



Press Releases


Corporate Video





Investors



Press Releases


Events & Presentations


Corporate Governance



Leadership


Board of Directors


Committee Composition





Financials & Filings



Financial Reports


Quarterly Results





Analyst Coverage


Stock Information



Stock Chart





FAQs







Careers


Contact











Home


About Us



Leadership


Board of Directors


Scientific Advisory Board


Culture


Global Headquarters


Community Affairs





Pipeline



Clinical Trials


Access to Our Investigational Agents





Technology



Immunotherapy


LADD


STING Pathway


B-select Antibodies


Scientific Publications


Intellectual Property





Partnerships


Media



Press Releases


Corporate Video





Investors



Press Releases


Events & Presentations


Corporate Governance



Leadership


Board of Directors


Committee Composition





Financials & Filings



Financial Reports


Quarterly Results





Analyst Coverage


Stock Information



Stock Chart





FAQs





Careers


Contact


Privacy Policy


Terms and Conditions of Use








© 2017 Aduro BiotechAll rights reserved


Privacy Policy


Terms and Conditions of Use


Website Design: Hane Chow, Inc.

TwitterLinkedIn



























Thomas W. Dubensky Jr. Ph.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Thomas W. Dubensky Jr. Ph.D.
Chief Scientific Officer at Aduro Biotech


View Full Profile
Are you Thomas W. Dubensky Jr. Ph.D.? Claim your profile


 


Sign up for Equilar Atlas and view Thomas W. Dubensky Jr. Ph.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Thomas W. Dubensky Jr. Ph.D.'s  network and community.
												FOLLOW changes in Thomas W. Dubensky Jr. Ph.D.'s employment and money-in-motion.
												CONNECT with Thomas W. Dubensky Jr. Ph.D. through your network of contacts.
												








Thomas W. Dubensky Jr. Ph.D.'s Executive Work History


Current


Chief Scientific Officer, 
Aduro Biotech


Past
To view Thomas W. Dubensky Jr. Ph.D.'s complete executive work history, sign up now
Age
59

 
 


Thomas W. Dubensky Jr. Ph.D.'s Biography



Thomas W. Dubensky, Jr., Ph.D. has served as our Chief Scientific Officer since September 2011. From 2009 to 2011, Dr. Dubensky served as Chief Scientific Officer of Immune Design Corp., a biotechnology company, where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. He was a co-founder and Chief Scientific Officer of Anza Therapeutics, Inc., a biotechnology company which was spun out from Cerus Corporation in 2007, where he served as the Vice President of Research beginning in 2002. At Cerus and at Anza, he helped to develop ...
(Read More)

			Thomas W. Dubensky, Jr., Ph.D. has served as our Chief Scientific Officer since September 2011. From 2009 to 2011, Dr. Dubensky served as Chief Scientific Officer of Immune Design Corp., a biotechnology company, where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. He was a co-founder and Chief Scientific Officer of Anza Therapeutics, Inc., a biotechnology company which was spun out from Cerus Corporation in 2007, where he served as the Vice President of Research beginning in 2002. At Cerus and at Anza, he helped to develop vaccine platforms based on attenuated strains of Listeria monocytogenes, which serve as the technology basis for Aduro. Previously, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses and plasmid DNA in positions of increasing responsibility at Viagene Biotech, Inc., Chiron Corporation and Onyx Pharmaceuticals, Inc., all biotechnology companies. Dr. Dubensky has co-authored more than 70 scientific papers and is an inventor on more than 30 issued U.S. patents and multiple pending applications. Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley; he earned his Ph.D. at the University of Colorado Health Sciences Center; and he was a post-doctoral fellow at Harvard Medical School in the Department of Pathology.
		
Source: Aduro Biotech on 04/28/2016
		
	

 






Sign up for Equilar Atlas and view Thomas W. Dubensky Jr. Ph.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Thomas W. Dubensky Jr. Ph.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Thomas W. Dubensky Jr. Ph.D.'s  network and community.
												FOLLOW changes in Thomas W. Dubensky Jr. Ph.D.'s employment and money-in-motion.
												CONNECT with Thomas W. Dubensky Jr. Ph.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Thomas W. Dubensky Jr. Ph.D.


















Thomas W. Dubensky Jr. Ph.D.'s Connections (12)





Sign up now to view Thomas W. Dubensky Jr. Ph.D.'s 12 connections »









Frank McCormick
Former Board Member, Aduro Biotech









Gerald Chan
Former Board Member, Aduro Biotech









Stephanie M. O'Brien
Former Board Member, Aduro Biotech









Blaine Templeman
Executive Vice President, Secretary and General Counsel, Aduro Biotech









William M. Greenman
Dir., President and Chief Executive Officer, Cerus Corporation









Stephen T. Isaacs
Chairman of the Board, President and Chief Executive Officer, Aduro Biotech









Ross Haghighat
Board Member, Aduro Biotech









Gregory W. Schafer
Chief Operating Officer, Aduro Biotech









Stephen A. Sherwin
Board Member, Neurocrine Biosciences, Inc.









Natalie Sacks
Chief Medical Officer, Aduro Biotech








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft









﻿






























Brokerages Set Aduro Biotech, Inc. (NASDAQ:ADRO) Price Target at $19.00 - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for Aduro Biotech Inc.

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor Aduro Biotech Inc. with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

Zacks: Osisko Gold Royalties Ltd (OR) Receives Consensus Recommendation of “Strong Buy” from Brokerages
First Trust Advisors LP Has $466,000 Position in Career Education Corporation (CECO)
Safeguard Scientifics, Inc. (SFE) Stake Maintained by State Board of Administration of Florida Retirement System
Great West Life Assurance Co. Can Has $120,000 Position in CoBiz Financial Inc. (NASDAQ:COBZ)
$0.03 Earnings Per Share Expected for Eros International PLC (EROS) This Quarter
Brokerages Set Schneider National Inc (SNDR) Price Target at $22.63
Brokerages Set Aduro Biotech, Inc. (NASDAQ:ADRO) Price Target at $19.00
Analysts Set Carolina Financial Corporation (CARO) Price Target at $33.13
Hartford Financial Services Group, Inc. (The) (NYSE:HIG) Receives $54.44 Consensus PT from Analysts
Synaptics Incorporated (SYNA) Lowered to “Sell” at Zacks Investment Research
Abbott Laboratories (ABT) Receives New Coverage from Analysts at Guggenheim
Sequential Brands Group, Inc. (SQBG) Lifted to “Buy” at Zacks Investment Research
Kier Group plc (KIE) Upgraded by Numis Securities Ltd to “Buy”
Ssab Svenskt (SSAAY) Downgraded by Zacks Investment Research
Wipro Limited (WIT) Rating Increased to Hold at Zacks Investment Research
Ahold NV (ADRNY) Upgraded to Buy by Zacks Investment Research
K&S AG (KPLUF) Stock Rating Upgraded by Societe Generale
KUEHNE&NAGEL INTL (KHNGY) Upgraded by Zacks Investment Research to “Buy”
WNS (Holdings) Limited (WNS) Downgraded to “Hold” at Zacks Investment Research
Infineon Technologies AG (ETR:IFXA) PT Set at €21.00 by Credit Suisse Group







Brokerages Set Aduro Biotech, Inc. (NASDAQ:ADRO) Price Target at $19.00


					Posted by Joanna Charbonneau on Jul 20th, 2017 // No Comments




Aduro Biotech, Inc. (NASDAQ:ADRO) has been given an average rating of “Buy” by the eight analysts that are presently  covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating.  The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $19.00. 
A number of research firms have weighed in on ADRO. Cowen and Company began coverage on shares of Aduro Biotech in a research note on Tuesday. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, July 4th. Canaccord Genuity  set a $30.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Monday, March 27th. HC Wainwright began coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They set a “buy” rating and a $18.00 price target on the stock. Finally, Rodman & Renshaw began coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They set a “buy” rating and a $18.00 price target on the stock.


 Get Aduro Biotech Inc. alerts:



COPYRIGHT VIOLATION NOTICE: This story was  published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/07/20/brokerages-set-aduro-biotech-inc-nasdaqadro-price-target-at-19-00.html. 





In other Aduro Biotech news, insider Thomas W. Dubensky sold 5,699 shares of the firm’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $9.92, for a total transaction of $56,534.08. Following the completion of the transaction, the insider now directly owns 41,300 shares of the company’s stock, valued at approximately $409,696. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Dirk G. Brockstedt sold 8,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $9.72, for a total transaction of $77,760.00. Following the transaction, the executive vice president now directly owns 57,300 shares of the company’s stock, valued at $556,956. The disclosure for this sale can be found here. Insiders have sold a total of 419,205 shares of company stock worth $4,410,591 in the last ninety days. 6.60% of the stock is currently owned by insiders. 
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tudor Investment Corp Et Al bought a new position in shares of  Aduro Biotech during the fourth quarter valued at $131,000.  Quantitative Systematic Strategies LLC bought a new position in shares of  Aduro Biotech during the first quarter valued at $145,000.  Daiwa SB Investments Ltd. bought a new position in shares of  Aduro Biotech during the first quarter valued at $153,000.  Creative Planning raised its position in shares of  Aduro Biotech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 6,375 shares in the last quarter.  Finally, Parametric Portfolio Associates LLC raised its position in shares of  Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 2,119 shares in the last quarter. 35.65% of the stock is owned by institutional investors. 
Shares of Aduro Biotech (ADRO) traded up 1.86% during mid-day trading on Monday, reaching $13.70. The company’s stock had a trading volume of 262,010 shares. The company’s market capitalization is $957.81 million. The firm’s 50 day moving average price is $11.45 and its 200-day moving average price is $10.85. Aduro Biotech has a 1-year low of $8.75 and a 1-year high of $16.43. 
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.07. The company had revenue of $3.77 million for the quarter, compared to the consensus estimate of $3.74 million. Aduro Biotech had a negative net margin of 166.85% and a negative return on equity of 35.35%.  On average, analysts predict that  Aduro Biotech will post ($1.41) EPS for the current year. 
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.






Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 















































Publications Authored by Thomas W Dubensky | PubFacts.com








































Thomas W Dubensky
 Are you  Thomas W Dubensky?   Register this Author




Register this Author






Earle A. Chiles Research InstituteUnited States 






Toggle navigation










Publications
















Publications
















41Publications


323Reads



 OF 






















A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
Authors:
Jeremy B Foote,
Marleen Kok,
James M Leatherman,
Todd D Armstrong,
Bridget C Marcinkowski,
Laureen S Ojalvo,
David B Kanne,
Elizabeth M Jaffee,
Thomas W Dubensky,
Leisha A EmensCancer Immunol Res 2017 Jun 8;5(6):468-479. Epub 2017 May 8.Department of Oncology, Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland. June 2017




Download Full Paper











Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele".
Authors:
Kelsey E Sivick,
Natalie H Surh,
Anthony L Desbien,
Eric P Grewal,
George E Katibah,
Sarah M McWhirter,
Thomas W DubenskyJ Immunol 2017 Jun;198(11):4183-4185STING Program, Aduro Biotech, Inc., Berkeley, CA 94710.June 2017




Download Full Paper











New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016.
Authors:
Prasad S Adusumilli,
Edward Cha,
Mark Cornfeld,
Thomas Davis,
Adi Diab,
Thomas W Dubensky,
Elizabeth Evans,
Jane L Grogan,
Bryan A Irving,
Rom S Leidner,
Shane A Olwill,
Patrick Soon-Shiong,
Frederic Triebel,
David Tuck,
Adrian Bot,
Roger D Dansey,
Charles G Drake,
Gordon J Freeman,
Ramy Ibrahim,
Salil Patel,
Daniel S ChenJ Immunother Cancer 2017  20;5:50. Epub 2017 Jun 20.Genentech/Roche, 1 DNA Way, South San Francisco, CA 94080 USA.June 2017




Download Full Paper











The host STING pathway at the interface of cancer and immunity.
Authors:
Leticia Corrales,
Sarah M McWhirter,
Thomas W Dubensky,
Thomas F GajewskiJ Clin Invest 2016 Jul 1;126(7):2404-11. Epub 2016 Jul 1.July 2016




Download Full Paper











STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Authors:
Emily Curran,
Xiufen Chen,
Leticia Corrales,
Douglas E Kline,
Thomas W Dubensky,
Priyanka Duttagupta,
Marcin Kortylewski,
Justin KlineCell Rep 2016 Jun 2;15(11):2357-66. Epub 2016 Jun 2.Department of Medicine, University of Chicago, Chicago, IL 60637, USA; Committee on Immunology, University of Chicago, Chicago, IL 60637, USA. Electronic address: June 2016




Download Full Paper











Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.
Authors:
Leticia Corrales,
Seng-Ryong Woo,
Jason B Williams,
Sarah M McWhirter,
Thomas W Dubensky,
Thomas F GajewskiJ Immunol 2016 Apr 29;196(7):3191-8. Epub 2016 Feb 29.Department of Pathology, The University of Chicago, Chicago, IL 60637; Section of Hematology/Oncology 2, Department of Medicine, The University of Chicago, Chicago, IL 60637 April 2016




Download Full Paper











Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.
Authors:
Christopher M Jackson,
Christina M Kochel,
Christopher J Nirschl,
Nicholas M Durham,
Jacob Ruzevick,
Angela Alme,
Brian J Francica,
Jimmy Elias,
Andrew Daniels,
Thomas W Dubensky,
Peter Lauer,
Dirk G Brockstedt,
Emily G Baxi,
Peter A Calabresi,
Janis M Taube,
Carlos A Pardo,
Henry Brem,
Drew M Pardoll,
Michael Lim,
Charles G DrakeClin Cancer Res 2016 Mar 21;22(5):1161-72. Epub 2015 Oct 21.Department of Oncology, Johns Hopkins University, Baltimore, Maryland. Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland.  March 2016




Download Full Paper











Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.
Authors:
Jason R Baird,
David Friedman,
Benjamin Cottam,
Thomas W Dubensky,
David B Kanne,
Shelly Bambina,
Keith Bahjat,
Marka R Crittenden,
Michael J GoughCancer Res 2016 Jan 13;76(1):50-61. Epub 2015 Nov 13.Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, Oregon. January 2016




Download Full Paper











Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Authors:
Leticia Corrales,
Laura Hix Glickman,
Sarah M McWhirter,
David B Kanne,
Kelsey E Sivick,
George E Katibah,
Seng-Ryong Woo,
Edward Lemmens,
Tamara Banda,
Justin J Leong,
Ken Metchette,
Thomas W Dubensky,
Thomas F GajewskiCell Rep 2015 May 7;11(7):1018-30. Epub 2015 May 7.Department of Pathology, The University of Chicago, 929 E57th Street GCIS 3H, Chicago, IL 60637, USA. Electronic address: May 2015




Download Full Paper











STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
Authors:
Juan Fu,
David B Kanne,
Meredith Leong,
Laura Hix Glickman,
Sarah M McWhirter,
Edward Lemmens,
Ken Mechette,
Justin J Leong,
Peter Lauer,
Weiqun Liu,
Kelsey E Sivick,
Qi Zeng,
Kevin C Soares,
Lei Zheng,
Daniel A Portnoy,
Joshua J Woodward,
Drew M Pardoll,
Thomas W Dubensky,
Young KimSci Transl Med 2015 Apr;7(283):283ra52Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA. Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.  April 2015




Download Full Paper











Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
Authors:
Jared M Odegard,
Brenna Kelley-Clarke,
Semih U Tareen,
David J Campbell,
Patrick A Flynn,
Christopher J Nicolai,
Megan M Slough,
Chintan D Vin,
Patrick J McGowan,
Lisa T Nelson,
Jan Ter Meulen,
Thomas W Dubensky,
Scott H RobbinsJ Immunother 2015 Feb-Mar;38(2):41-53*Immune Design Corp. †TRIA Bioscience Corp., Seattle, WA.February 2015




Download Full Paper











Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.
Authors:
Elizabeth A Miller,
Meredith R Spadaccia,
Thomas Norton,
Morgan Demmler,
Ramya Gopal,
Meagan O'Brien,
Nathaniel Landau,
Thomas W Dubensky,
Peter Lauer,
Dirk G Brockstedt,
Nina BhardwajAIDS Res Hum Retroviruses 2015 Jan;31(1):127-361 Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai , New York, New York.January 2015




Download Full Paper











A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
Authors:
Bridget P Keenan,
Yvonne Saenger,
Michel I Kafrouni,
Ashley Leubner,
Peter Lauer,
Anirban Maitra,
Agnieszka A Rucki,
Andrew J Gunderson,
Lisa M Coussens,
Dirk G Brockstedt,
Thomas W Dubensky,
Raffit Hassan,
Todd D Armstrong,
Elizabeth M JaffeeGastroenterology 2014 Jun 6;146(7):1784-94.e6. Epub 2014 Mar 6.The Sidney Kimmel Comprehensive Cancer Center, the Skip Viragh Center for Clinical Pancreatic Cancer Research, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, Maryland. Electronic address: June 2014




Download Full Paper











Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.
Authors:
Semih U Tareen,
Brenna Kelley-Clarke,
Christopher J Nicolai,
Linda A Cassiano,
Lisa T Nelson,
Megan M Slough,
Chintan D Vin,
Jared M Odegard,
Derek D Sloan,
Neal Van Hoeven,
James M Allen,
Thomas W Dubensky,
Scott H RobbinsMol Ther 2014 Mar 6;22(3):575-87. Epub 2013 Dec 6.1] Immune Design Corp., Seattle, Washington, USA [2] TRIA Bioscience Corp., Seattle, Washington, USA.March 2014




Download Full Paper











Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.
Authors:
Thomas W Dubensky,
David B Kanne,
Meredith L LeongTher Adv Vaccines 2013 Nov;1(4):131-43Aduro BioTech, Inc., Berkeley, CA, USA.November 2013




Download Full Paper











Killed but metabolically active vaccines.
Authors:
Thomas W Dubensky,
Justin Skoble,
Peter Lauer,
Dirk G BrockstedtCurr Opin Biotechnol 2012 Dec 18;23(6):917-23. Epub 2012 May 18.Aduro BioTech, Inc., Berkeley, CA 94710, United States. December 2012




Download Full Paper











A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Authors:
Dung T Le,
Dirk G Brockstedt,
Ran Nir-Paz,
Johannes Hampl,
Shruti Mathur,
John Nemunaitis,
Daniel H Sterman,
Raffit Hassan,
Eric Lutz,
Bentley Moyer,
Martin Giedlin,
Jana-Lynn Louis,
Elizabeth A Sugar,
Alice Pons,
Andrea L Cox,
Jordana Levine,
Aimee Luck Murphy,
Peter Illei,
Thomas W Dubensky,
Joseph E Eiden,
Elizabeth M Jaffee,
Daniel A LaheruClin Cancer Res 2012 Feb 6;18(3):858-68. Epub 2011 Dec 6.The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA. February 2012




Download Full Paper











Adjuvants for cancer vaccines.
Authors:
Thomas W Dubensky,
Steven G ReedSemin Immunol 2010 Jun 21;22(3):155-61. Epub 2010 May 21.Immune Design Corporation, 1124 Columbia St., Ste. 700, Seattle, WA 98104, United States.June 2010




Download Full Paper











Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Authors:
Gomathinayagam Sinnathamby,
Peter Lauer,
Jennifer Zerfass,
Bill Hanson,
Aykan Karabudak,
Jonathan Krakover,
Angeles Alvarez Secord,
Timothy M Clay,
Michael A Morse,
Thomas W Dubensky,
Dirk G Brockstedt,
Ramila Philip,
Martin GiedlinJ Immunother 2009 Oct;32(8):856-69Immunotope, Inc, The Pennsylvania Biotechnology Center, Doylestown, PA 18902, USA.October 2009




Download Full Paper











Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice.
Authors:
Meredith L Leong,
Johannes Hampl,
Weiqun Liu,
Shruti Mathur,
Keith S Bahjat,
William Luckett,
Thomas W Dubensky,
Dirk G BrockstedtInfect Immun 2009 Sep 15;77(9):3958-68. Epub 2009 Jun 15.Anza Therapeutics, Concord, California, USA. September 2009




Download Full Paper











Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria.
Authors:
Keith S Bahjat,
Nicole Meyer-Morse,
Edward E Lemmens,
Jessica A Shugart,
Thomas W Dubensky,
Dirk G Brockstedt,
Daniel A PortnoyPLoS Pathog 2009 Sep 4;5(9):e1000568. Epub 2009 Sep 4.Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center, Portland, Oregon, United States of America. September 2009




Download Full Paper











Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
Authors:
Justin Skoble,
John W Beaber,
Yi Gao,
Julie A Lovchik,
Laurie E Sower,
Weiqun Liu,
William Luckett,
Johnny W Peterson,
Richard Calendar,
Daniel A Portnoy,
C Rick Lyons,
Thomas W DubenskyInfect Immun 2009 Apr 21;77(4):1649-63. Epub 2009 Jan 21.Anza Therapeutics Incorporated, Concord, California 94520, USA. April 2009




Download Full Paper











KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
Authors:
Mojca Skoberne,
Alice Yewdall,
Keith S Bahjat,
Emmanuelle Godefroy,
Peter Lauer,
Edward Lemmens,
Weiqun Liu,
Will Luckett,
Meredith Leong,
Thomas W Dubensky,
Dirk G Brockstedt,
Nina BhardwajJ Clin Invest 2008 Dec 6;118(12):3990-4001. Epub 2008 Nov 6.Cancer Institute, New York University School of Medicine, New York, New York 10016, USA. December 2008




Download Full Paper











Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Authors:
Dirk G Brockstedt,
Thomas W DubenskyExpert Rev Vaccines 2008 Sep;7(7):1069-84Anza Therapeutics, Inc., 2550 Stanwell Drive, Concord, CA 94520, USA. September 2008




Download Full Paper











Constitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains.
Authors:
Peter Lauer,
Bill Hanson,
Edward E Lemmens,
Weiqun Liu,
William S Luckett,
Meredith L Leong,
Heather E Allen,
Justin Skoble,
Keith S Bahjat,
Nancy E Freitag,
Dirk G Brockstedt,
Thomas W DubenskyInfect Immun 2008 Aug 9;76(8):3742-53. Epub 2008 Jun 9.Anza Therapeutics, Inc., Concord, CA 94520, USA. August 2008




Download Full Paper











Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity.
Authors:
Gregory T Crimmins,
Anat A Herskovits,
Kai Rehder,
Kelsey E Sivick,
Peter Lauer,
Thomas W Dubensky,
Daniel A PortnoyProc Natl Acad Sci U S A 2008 Jul 16;105(29):10191-6. Epub 2008 Jul 16.Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.July 2008




Download Full Paper











Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.
Authors:
Keith S Bahjat,
Rodney A Prell,
Heather E Allen,
Weiqun Liu,
Edward E Lemmens,
Meredith L Leong,
Daniel A Portnoy,
Thomas W Dubensky,
Dirk G Brockstedt,
Martin A GiedlinJ Immunol 2007 Dec;179(11):7376-84Cerus Corporation, Concord, CA 94520, USA. December 2007




Download Full Paper











Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
Authors:
Monica V Goldberg,
Charles H Maris,
Edward L Hipkiss,
Andrew S Flies,
Lijie Zhen,
Rubin M Tuder,
Joseph F Grosso,
Timothy J Harris,
Derese Getnet,
Katharine A Whartenby,
Dirk G Brockstedt,
Thomas W Dubensky,
Lieping Chen,
Drew M Pardoll,
Charles G DrakeBlood 2007 Jul 28;110(1):186-92. Epub 2007 Mar 28.Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.July 2007




Download Full Paper











Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
Authors:
Lynette Sawyer,
Deborah Hanson,
Grace Castro,
William Luckett,
Thomas W Dubensky,
Adonis StassinopoulosTransfusion 2007 Jun;47(6):1062-70Cerus Corporation, Concord, California 94520, USA. June 2007




Download Full Paper











Cytosolic entry controls CD8+-T-cell potency during bacterial infection.
Authors:
Keith S Bahjat,
Weiqun Liu,
Edward E Lemmens,
Stephen P Schoenberger,
Daniel A Portnoy,
Thomas W Dubensky,
Dirk G BrockstedtInfect Immun 2006 Nov 5;74(11):6387-97. Epub 2006 Sep 5.Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520, USA. November 2006




Download Full Paper











Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.
Authors:
Camie W Chan,
Emily Crafton,
Hong-Ni Fan,
James Flook,
Kiyoshi Yoshimura,
Mario Skarica,
Dirk Brockstedt,
Thomas W Dubensky,
Monique F Stins,
Lewis L Lanier,
Drew M Pardoll,
Franck HousseauNat Med 2006 Feb 29;12(2):207-13. Epub 2006 Jan 29.Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB-440, 1650 Orleans Street, Baltimore, Maryland 21231, USA.February 2006




Download Full Paper











Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.
Authors:
Kiyoshi Yoshimura,
Ajay Jain,
Heather E Allen,
Lindsay S Laird,
Christina Y Chia,
Sowmya Ravi,
Dirk G Brockstedt,
Martin A Giedlin,
Keith S Bahjat,
Meredith L Leong,
Jill E Slansky,
David N Cook,
Thomas W Dubensky,
Drew M Pardoll,
Richard D SchulickCancer Res 2006 Jan;66(2):1096-104Immunology and Hematopoiesis Division, Department of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA.January 2006




Download Full Paper











Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
Authors:
Dirk G Brockstedt,
Martin A Giedlin,
Meredith L Leong,
Keith S Bahjat,
Yi Gao,
William Luckett,
Weiqun Liu,
David N Cook,
Daniel A Portnoy,
Thomas W DubenskyProc Natl Acad Sci U S A 2004 Sep 13;101(38):13832-7. Epub 2004 Sep 13.Cerus, Concord, CA 94520, USA. September 2004




Download Full Paper











Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.
Authors:
Holly Starks,
Kevin W Bruhn,
Hao Shen,
Ronald A Barry,
Thomas W Dubensky,
Dirk Brockstedt,
David J Hinrichs,
Darren E Higgins,
Jeffrey F Miller,
Martin Giedlin,
H G Archie BouwerJ Immunol 2004 Jul;173(1):420-7Veterans Affairs Medical Center, Earle A. Chiles Research Institute, Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, OR 97201, USA.July 2004




Download Full Paper











An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
Authors:
Silvia Perri,
Catherine E Greer,
Kent Thudium,
Barbara Doe,
Harold Legg,
Hong Liu,
Raul E Romero,
Zequn Tang,
Qian Bin,
Thomas W Dubensky,
Michael Vajdy,
Gillis R Otten,
John M PoloJ Virol 2003 Oct;77(19):10394-403Vaccine Research, Chiron Corporation, Emeryville, California 94608, USA. October 2003




Download Full Paper











Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?
Authors:
Martin A Giedlin,
David N Cook,
Thomas W DubenskyCancer Cell 2003 Oct;4(4):241-3Cancer Research, Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520, USA.October 2003




Download Full Paper











Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
Authors:
Wolfgang W Leitner,
Leroy N Hwang,
Michael J deVeer,
Aimin Zhou,
Robert H Silverman,
Bryan R G Williams,
Thomas W Dubensky,
Han Ying,
Nicholas P RestifoNat Med 2003 Jan 23;9(1):33-9. Epub 2002 Dec 23.National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. January 2003




Download Full Paper











Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer.
Authors:
Thomas W Dubensky,
Sybille L SauterMethods Mol Med 2003 ;76:309-30Cerus Corporation, Concord, CA, USA.January 2003




Download Full Paper











A highly efficient gene delivery system derived from feline immunodeficiency virus (FIV).
Authors:
Sybille L Sauter,
Mehdi Gasmi,
Thomas W DubenskyMethods Mol Med 2003 ;76:405-32GenStar Therapeutics Inc., San Diego, CA, USA.January 2003




Download Full Paper











Virus-based vectors for human vaccine applications.
Authors:
John M Polo,
Thomas W DubenskyDrug Discov Today 2002 Jul;7(13):719-27Chiron Corporation, Immunology and Infectious Diseases, 4560 Horton St, Emeryville, CA 94608, USA. July 2002




Download Full Paper











(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease.
Authors:
Thomas W DubenskyCancer Cell 2002 May;1(4):307-9Cancer Research, Cerus Corporation, 2411 Stanwell Dr., Concord, CA 94520, USA. May 2002




Download Full Paper



 






















 OF 











